This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Enzo Biochem Announces Upcoming Litigation Schedule

Enzo Biochem, Inc. (NYSE:ENZ) (“Enzo”, “the Company”) today issued an update on its ongoing litigation surrounding the protection of its intellectual property and contractual rights. Two of the cases, in which Enzo is the Plaintiff, are scheduled for jury trials. Both cases will be tried in the United States District Court for the Southern District of New York in New York City.

  • In the case of Enzo Biochem v. PerkinElmer, 03-cv-03817, the Court has scheduled a jury trial to begin March 18, 2014.
  • In the case of Enzo Life Sciences v. Affymetrix, 04-cv-01555, a jury trial has been scheduled for May 5, 2014.

Enzo sued PerkinElmer for, among other things, breach of contract and patent infringement, claiming that the company was subject to an agreement to distribute Enzo’s patented nucleotide labeling technologies for research purposes, but then distributed the technologies for clinical use without Enzo’s authorization. Enzo sued Affymetrix for, among other things, breaching their distribution agreement by misappropriating Enzo technologies and manufacturing and selling Enzo products in violation of the terms of the agreement.

In a recent ruling, another Federal Court, the United States District Court for the District of Connecticut, awarded Enzo over $61.0 million in damages and interest in connection with Enzo’s patent infringement lawsuit against Applera Corp., now Life Technologies, Inc.

About Enzo Biochem

Enzo Biochem is a pioneer in molecular diagnostics, leading the convergence of clinical laboratories, life sciences and therapeutics through the development of unique diagnostic platform technologies that provide numerous advantages over previous standards. A global company, Enzo Biochem utilizes cross-functional teams to develop and deploy products systems and services that meet the ever-changing and rapidly growing needs of health care both today and into the future. Underpinning Enzo Biochem’s products and technologies is a broad and deep intellectual property portfolio, with patent coverage across a number of key enabling technologies.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,126.12 -36.87 -0.20%
S&P 500 2,120.79 -2.69 -0.13%
NASDAQ 5,097.9760 -8.6170 -0.17%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs